The global demand for Emergency Contraceptive Pills Market is presumed to reach the valuation of nearly USD XX MN by 2028 from USD XX MN in 2021 with a CAGR of XX% during the period of 2022-2028.
Emergency contraceptive pills (ECPs), often called the morning-after pill, can be taken to prevent pregnancy after unprotected sex. Generally, ECPs can be taken up to 72-120 hours or five days after having unprotected sex but not useful if sex happens after taking the ECPs. These pills delay ovulation processing to interrupt the pregnancy only if fertilization and implantation have not already occurred. Consuming ECPs cannot be used as a regular birth control method to induce abortion or protect against sexually transmitted diseases. There are no age limits for the use of ECPs, and they do not harm future fertility. Frequent use of ECPs can result in several side-effects, such as menstrual irregularities.
Rising awareness about contraception methods in emerging economies and government initiatives to improve access to these products are the significant trends accelerating this market’s growth. The promotion of affordable and high-quality healthcare services for women around the world will boost market growth. The WHO's recommendation to integrate ECPs into health care services for populations most at risk of exposure to unprotected sex will further propel market growth. The surge in the number of unplanned pregnancies across the globe due to changing cultural patterns will benefit market growth. The high efficiency (99%) of these pills on timely consumption will create market growth opportunities. The lack of awareness and the side effects associated with the frequent use of ECPs will hamper market growth.
The report covers Porter’s Five Forces Model, Market Attractiveness Analysis and Value Chain analysis. These tools help to get a clear picture of the industry’s structure and evaluate the competition attractiveness at a global level.
Additionally, these tools also give inclusive assessment of each application/product segment in the global market of emergency contraceptive pills.
The entire emergency contraceptive pills market has been sub-categorized into product type and sales channel. The report provides an analysis of these subsets with respect to the geographical segmentation. This research study will keep marketer informed and helps to identify the target demographics for a product or service.
By Product Type
By Sales Channel
- Combination Pills
- Progesterone Pills
- Estrogen Pills
- Other Products
- Drug Stores/ Pharmacy
- Hospital Pharmacies
- Online Traders
This section covers regional segmentation which accentuates on current and future demand for emergency contraceptive pills market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand for individual application segment across all the prominent regions.
Global Emergency Contraceptive Pills Market Share by Region (Representative Graph)
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the emergency contraceptive pills market include Teva Pharmaceutical Industries Ltd., Bayer AG, HRA Pharma, Piramal Enterprises Limited, Mankind Pharma Ltd., Richter Gedeon Nyrt, Lupin Limited, Cooper Pharma, Pfizer Inc., Zhejiang Xianju Pharmaceutical Co., Others. This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
This market research report has been produced by gathering information on the basis of primary and secondary research. Secondary research has been done by using various sources which include (but not limited to) Company Websites, Paid Data Sources, Technical Journals, Financial Reports, SEC Filings, and other different industry publications.
If specific information is required which is not currently within the scope of the report, it can be provided as a part of customization.